Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Turoctocog Alfa in Chinese Patients With Haemophilia A
NCT02938585Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Dec 2016
- Primary completion
- Mar 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of turoctocog alfa in hemophilia A (2 arms), sponsored by Novo Nordisk. Primary endpoint: Haemostatic Effect of Turoctocog Alfa (Treatment of Bleeds) at 6 months. Started Dec 2016; status: completed.
02
Drugs
turoctocog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT02938585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02938585.